Cyclo Therapeutics Stock (NASDAQ:CYTH)

Forecast Revenue Financials Chart

Previous Close

$0.66

52W Range

$0.57 - $2.12

50D Avg

$0.70

200D Avg

$1.07

Market Cap

$18.12M

Avg Vol (3M)

$32.92K

Beta

-0.38

Div Yield

CYTH Company Profile

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

May 03, 2000

Website

CYTH Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Mar 20
Trappsol Cyclo	$30.10K
Product and Service, Other	$2.57K
Trappsol Fine Chemical	$78.11K
Trappsol HPB	$214.96K

Fiscal year ends in Dec 23 | Currency in USD

CYTH Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	$1.08M	$1.38M	$1.59M
Operating Income	$-20.05M	$-15.61M	$-14.27M
Net Income	$-20.06M	$-15.28M	$-14.31M
EBITDA	$-20.05M	$-15.75M	$-14.23M
Basic EPS	$-1.23	$-2.40	$-2.25
Diluted EPS	$-1.23	$-2.40	$-2.25

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

Ticker	Company
AQST	Aquestive Therapeutics, Inc.
PAHC	Phibro Animal Health Corporation
PTPI	Petros Pharmaceuticals, Inc.
ITCI	Intra-Cellular Therapies, Inc.
TKNO	Alpha Teknova, Inc.
AMRX	Amneal Pharmaceuticals, Inc.
LFCR	Lifecore Biomedical, Inc.
IRWD	Ironwood Pharmaceuticals, Inc.
ASRT	Assertio Holdings, Inc.